Skip to main content

Table 2 Stratified meta-analysis of circulating apelin, chemerin and omentin levels in GDM

From: Circulating apelin, chemerin and omentin levels in patients with gestational diabetes mellitus: a systematic review and meta-analysis

Subgroups

N

Test of association

  

Test of heterogeneity

 

SMD (95% CI)

z

P

Q

I2(%)

P

Apelin

Ethnicity

 Caucasian

2

0.01 (− 0.40 to 1.26)

0.06

0.95

0.02

0.00

0.88

 Asian

4

0.72 (− 0.77 to 2.22)

0.95

0.35

88.68

96.60

< 0.05

 Combined

6

0.43 (−0.40 to 1.26)

1.02

0.31

90.85

94.50

< 0.05

Age(mean,years) yyeyeyears)

 < 30

2

2.17 (−1.09 to 5.43)

1.31

0.19

30.23

88.20

< 0.05

 ≥ 30

4

−0.31 (− 0.93 to 0.31)

0.99

0.32

25.41

96.70

< 0.05

 Combined

6

0.43 (− 0.40 to 1.26)

1.02

0.31

90.85

94.50

< 0.05

BMI(mean,kg/m2)

 < 28

4

−0.14 (− 0.85 to 0.57)

0.39

0.70

35.40

91.50

< 0.05

 ≥ 28

2

1.84 (−2.09 to 5.77)

0.92

0.36

41.58

97.60

< 0.05

 Combined

6

0.43 (−0.40 to 1.26)

1.02

0.31

90.85

94.50

< 0.05

Study type

 Case-control

4

0.10 (−0.17 to 0.36)

0.72

0.48

3.95

24.00

0.27

 Cohort

2

1.37 (−3.48 to 6.22)

0.55

0.58

74.68

98.70

< 0.05

 Combined

6

0.43 (−0.40 to 1.26)

1.02

0.31

90.85

94.50

< 0.05

Measurement type

 ELISA

4

0.72 (−0.77 to 2.22)

0.95

0.35

88.68

96.60

< 0.05

 RIA

2

0.01 (−0.25 to 0.26)

0.06

0.95

0.02

0.00

0.88

 Combined

6

0.43 (−0.40 to 1.26)

1.02

0.31

90.85

94.50

< 0.05

ELISA kits

Phoenix Pharmaceuticals

1

−1.08 (−1.42 to − 0.73)

6.16

< 0.01

0.02

0.00

0.23

Eastbiopharm

1

0.54 (0.03 to 1.06)

2.06

0.04

25.41

25.00

0.87

Bio-Tek Instruments

1

3.87 (2.80 to 4.94)

7.10

< 0.01

53.60

36.00

0.45

RayBiotech

1

−0.14 (− 0.72 to 0.45)

0.47

0.64

37.60

28.00

0.34

Combined

4

0.72 (−0.77 to 2.22)

0.95

0.34

88.68

96.60

< 0.05

Diagnostic criteria

 ADA

1

−1.07 (−1.42 to − 0.73)

6.16

< 0.05

0.00

NA

NA

 ACOG

2

2.17 (−1.09 to 5.43)

1.31

0.19

30.23

96.70

< 0.05

 C&C

1

−0.14 (− 0.73 to 0.45)

0.47

0.64

0.00

NA

NA

 WHO

2

0.01 (−0.25 to 0.26)

0.06

0.95

0.02

0.00

0.88

 Combined

6

0.43 (−0.40 to 1.26)

1.02

0.31

90.85

94.50

< 0.05

Measurement trimester

 Second

1

0.00 (−0.28 to 0.28)

0.00

1.00

89.44

95.50

< 0.05

 Third

5

0.57 (−0.62 to 1.76)

0.94

0.35

0.00

NA

NA

 Combined

6

0.43 (−0.40 to 1.26)

1.02

0.31

90.85

94.50

< 0.05

Chemerin

Ethnicity

 Caucasian

5

−0.00 (− 0.44 to 0.43)

0.01

0.99

19.03

79.00

< 0.05

 Asian

7

1.21 (0.09 to 2.35)

2.11

0.04

128.50

95.30

< 0.05

 Australoid

1

−1.76 (−2.17 to 1.36)

8.53

0.36

0.00

NA

NA

 African

1

2.69 (2.45 to 2.93)

21.74

< 0.05

0.00

NA

NA

 Combined

14

0.77 (−0.07 to 1.61)

1.80

0.07

651.01

98.00

< 0.05

Age(mean,years)

 < 30

9

1.51 (0.28 to 2.73)

2.41

0.02

306.13

97.40

< 0.05

 ≥ 30

5

−0.36 (−1.03 to 0.30)

1.07

0.28

75.12

94.70

< 0.05

 Combined

14

0.77 (−0.07 to 1.61)

1.80

0.07

651.01

98.00

< 0.05

BMI(mean,kg/m2)

 < 28

5

−0.75 (−1.62 to 0.11)

1.71

0.09

80.05

95.00

< 0.05

 ≥ 28

9

1.69 (0.58 to 2.79)

2.99

< 0.05

369.82

97.80

< 0.05

 Combined

14

0.77 (−0.07 to 1.61)

1.80

0.07

651.01

98.00

< 0.05

Study type

 Case-control

13

0.86 (−0.08 to 1.80)

1.79

0.07

636.04

98.10

< 0.05

 Cohort

1

−0.07 (− 0.36 to 0.23)

0.45

0.65

0.00

NA

NA

 Combined

14

0.77 (−0.07 to 1.61)

1.80

0.07

651.01

98.00

< 0.05

ELISA kits

Millipore

3

0.60 (− 0.50 to 1.71)

1.07

0.29

11.90

83.20

0.29

R&D systems

4

−0.11 (−1.64 to 1.41)

0.15

0.88

100.69

97.00

0.88

Sbjbio

3

2.94 (−2.25 to 0.12)

1.11

0.27

98.62

98.00

0.27

Biovendor

2

0.08 (−0.52 to 0.67)

0.26

0.80

5.78

82.70

0.80

other kits

2

1.11 (−1.97 to 4.20)

0.71

0.48

302.71

99.70

0.48

Combined

14

0.77 (−0.07 to 1.61)

1.80

0.07

651.01

98.00

0.07

Diagnostic criteria

 IADPSG

6

0.86 (− 0.72 to 2.43)

1.07

0.29

350.75

98.60

< 0.05

 ADIPS

1

1.26 (−2.17 to 1.36)

8.53

> 0.05

0.00

NA

NA

 ACOG

1

0.37 (0.06 to 0.69)

2.31

0.02

0.00

NA

NA

 ADA

4

2.27 (−0.46 to 4.99)

1.63

0.10

98.95

97.00

< 0.05

 NDDG

2

−0.13 (− 0.36 to 0.10)

1.10

0.27

0.46

0.00

0.49

 Combined

14

0.77 (−0.07 to 1.61)

1.80

0.07

651.01

98.00

< 0.05

Measurement trimester

 Second

8

1.09 (0.17 to 2.34)

1.70

0.04

484.85

98.60

< 0.05

 Third

6

0.40 (−0.61 to 1.41).

0.77

0.44

112.32

95.50

< 0.05

 Combined

14

0.77 (−0.07 to 1.61)

1.80

0.07

651.01

98.00

< 0.05

Omentin

Ethnicity

 Caucasian

6

−0.33 (−0.65 to − 0.02)

2.06

0.04

13.78

63.70

0.02

 Asian

2

−1.04 (−2.87 to 0.79)

1.11

0.27

16.82

94.10

< 0.05

 Australoid

2

− 1.36 (−6.07 to 3.35)

0.57

0.57

62.46

98.40

< 0.05

 Combined

10

−0.73 (−1.26 to − 0.20)

2.68

< 0.05

97.49

90.80

< 0.05

Age(mean,years)

 < 30

6

−0.75 (−1.36 to − 0.15)

2.44

0.02

27.75

82.00

< 0.05

 ≥ 30

4

−0.69 (−1.73 to 0.34)

1.31

0.19

68.06

95.60

< 0.05

 Combined

10

−0.73 (−1.26 to − 0.20)

2.68

< 0.05

97.49

90.80

< 0.05

BMI(mean,kg/m2)

 < 28

4

−2.06 (−3.76 to − 0.37)

2.38

0.02

59.74

95.00

< 0.05

 ≥ 28

6

−0.06 (− 0.38 to 0.27)

0.35

0.73

14.48

65.50

0.01

 Combined

10

−0.73 (−1.26 to − 0.20)

2.68

< 0.05

97.49

90.80

< 0.05

Study type

 Case-control

4

−0.57 (−1.20 to 0.05)

1.79

0.07

9.72

69.10

0.02

 Cohort

6

−0.79 (−1.58 to 0.10)

1.96

0.05

87.74

94.30

< 0.05

 Combined

10

−0.73 (−1.26 to 0.20)

2.68

> 0.05

97.49

90.80

< 0.05

Diagnostic criteria

 IADPSG

2

−1.33 (−3.30 to 0.65)

1.32

0.19

6.15

83.80

0.01

 C&C

2

−1.04 (−2.87 to 0.79)

1.11

0.27

16.82

94.10

< 0.05

 ADIPS

2

−1.36 (−6.07 to 3.35)

0.57

0.57

62.46

98.40

< 0.05

 ADA

2

−0.20 (− 0.56 to 0.17)

1.06

0.29

3.31

69.80

0.07

 WHO

2

−0.24 (− 0.55 to 0.08)

1.48

0.14

0.00

0.00

0.95

 Combined

10

−0.73 (−1.26 to − 0.20)

2.68

< 0.05

97.49

90.80

< 0.05

ELISA kits

 Millipore

2

−1.33 (−3.29 to 0.65)

1.32

0.18

6.15

83.80

0.01

 Cusabio

2

−1.36 (−6.07 to 3.35)

0.57

0.57

62.46

98.40

< 0.05

 Life Science

2

−0.19 (−0.56 to 0.17)

1.06

0.29

3.31

69.80

0.06

 Bio Vendor

2

−1.09 (−2.81 to 0.64)

1.24

0.21

16.53

94.00

< 0.05

 other kits

2

−0.16 (−0.53 to 0.20)

0.88

0.38

0.05

0.00

0.82

 Combined

10

−0.73 (−1.26 to − 0.19)

2.68

< 0.05

97.49

90.80

< 0.05

Measurement trimester

 Second

4

−0.12 (−0.31 to − 0.08)

1.19

0.04

84.73

94.10

< 0.05

 Third

6

−1.27 (−2.45 to 0.08)

2.10

0.23

1.10

0.00

0.78

 Combined

10

−0.73 (−1.26 to − 0.20)

2.68

< 0.05

97.49

90.80

< 0.05

  1. N Number of studies, SMD Standardized mean difference, BMI Body mass index, ELASA Enzyme linked immunosorbent assay, RIA Radioimmunoassay, NA Not available
Back to article page

Lipids in Health and Disease

ISSN: 1476-511X